Acquas E, Di Chiara G
Department of Toxicology, CNR Center for Neuropharmacology, University of Cagliari, Via le A. Diaz, 182-09126, Cagliari, Italy.
Eur J Pharmacol. 1999 Oct 27;383(2):121-7. doi: 10.1016/s0014-2999(99)00570-1.
The role of dopamine D(1) and D(2) receptors in the control of acetylcholine release in the dorsal striatum by endogenous dopamine was investigated by monitoring with microdialysis the effect of the separate or combined administration of the dopamine D(1) receptor antagonist, SCH 39166 ¿(-)-trans-6,7,7a,8,9, 13b-exahydro-3-chloro-2-hydroxy-N-methyl-5H-benzo-[d]-nap hto-[2, 1b]-azepine hydrochloride¿ (50 microg/kg subcutaneous (s.c.)), of the dopamine D(2)/D(3) receptor agonist, quinpirole (trans-(-)-4aR, 4a,5,6,7,8,8a,9-octahydro-5-propyl-1H-pyrazolo-(3,4-g)-quinoline hydrochloride) (5 and 10 microg/kg s.c.), and of the D(3) receptor selective agonist, PD 128,907 [S(+)-(4aR,10bR)-3,4,4a, 10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano-[4,3-b]-1,4-oxazin -9-ol hydrochloride] (50 microg/kg s.c.), on in vivo dopamine and acetylcholine release. Microdialysis was performed with a Ringer containing low concentrations (0.01 microM) of the acetylcholinesterase inhibitor, neostigmine. Quinpirole (10 microg/kg s.c.) decreased striatal dopamine and acetylcholine release. Administration of PD 128,907 (50 microg/kg) decreased dopamine but failed to affect acetylcholine release. SCH 39166 (50 microg/kg s.c.) stimulated dopamine release and reduced acetylcholine release. Pretreatment with quinpirole reduced (5 microg/kg s.c.) or completely prevented (10 microg/kg s.c.) the stimulation of dopamine release elicited by SCH 39166 (50 microg/kg s.c.); on the other hand, pretreatment with quinpirole (5 and 10 microg/kg) potentiated the reduction of striatal acetylcholine release induced by SCH 39166 (50 microg/kg s.c.). Similarly, pretreatment with PD 128,907 (50 microg/kg) which prevented the increase of dopamine release induced by SCH 39166 (50 microg/kg), potentiated the reduction of striatal acetylcholine transmission elicited by SCH 39166. Thus, pretreatment with low doses of quinpirole or PD 128,907 influences in opposite manner the effect of SCH 39166 on striatal dopamine and acetylcholine release, counteracting the increase of dopamine release and potentiating the decrease in acetylcholine release. These results provide further evidence for the existence of a tonic stimulatory input of endogenous dopamine on striatal acetylcholine transmission mediated by dopamine D(1) receptors.
通过微透析监测多巴胺D(1)受体拮抗剂SCH 39166((-)-反式-6,7,7a,8,9,13b-六氢-3-氯-2-羟基-N-甲基-5H-苯并[d]-萘并[2,1b]-氮杂卓盐酸盐)(50微克/千克皮下注射)、多巴胺D(2)/D(3)受体激动剂喹吡罗(反式(-)-4aR,4a,5,6,7,8,8a,9-八氢-5-丙基-1H-吡唑并[3,4-g]-喹啉盐酸盐)(5和10微克/千克皮下注射)以及D(3)受体选择性激动剂PD 128,907 [S(+)-(4aR,10bR)-3,4,4a,10b-四氢-4-丙基-2H,5H-[1]苯并吡喃并[4,3-b]-1,4-恶嗪-9-醇盐酸盐](50微克/千克皮下注射)单独或联合给药对体内多巴胺和乙酰胆碱释放的影响,研究内源性多巴胺在背侧纹状体中对乙酰胆碱释放控制过程中多巴胺D(1)和D(2)受体的作用。微透析采用含有低浓度(0.01微摩尔)乙酰胆碱酯酶抑制剂新斯的明的林格氏液进行。喹吡罗(10微克/千克皮下注射)可降低纹状体多巴胺和乙酰胆碱释放。给予PD 128,907(50微克/千克)可降低多巴胺,但未能影响乙酰胆碱释放。SCH 39166(50微克/千克皮下注射)刺激多巴胺释放并减少乙酰胆碱释放。用喹吡罗预处理(5微克/千克皮下注射)可降低(10微克/千克皮下注射)或完全阻止(10微克/千克皮下注射)由SCH 39166(50微克/千克皮下注射)引起的多巴胺释放刺激;另一方面,用喹吡罗(5和10微克/千克)预处理可增强由SCH 39166(50微克/千克皮下注射)诱导的纹状体乙酰胆碱释放减少。同样,用PD 128,907(50微克/千克)预处理可阻止由SCH 39166(50微克/千克)引起的多巴胺释放增加,增强由SCH 39166引起的纹状体乙酰胆碱传递减少。因此,用低剂量喹吡罗或PD 128,907预处理以相反方式影响SCH 39166对纹状体多巴胺和乙酰胆碱释放的作用,抵消多巴胺释放增加并增强乙酰胆碱释放减少。这些结果为内源性多巴胺通过多巴胺D(1)受体对纹状体乙酰胆碱传递存在紧张性刺激输入提供了进一步证据。